HBM Holdings Enhances Collaboration with AstraZeneca for Biotherapeutic Development
HBM Holdings Ltd. has announced an enhancement in its collaboration with AstraZeneca to develop next-generation biotherapeutics. The amendment to their agreement expands the partnership's scope while maintaining original economic terms, highlighting their commitment to biotechnology expertise. HBM Holdings focuses on innovative therapeutics, including antibody-drug conjugates and T cell engagers, with a market cap of HK$11.39B. The latest analyst rating for HBM Holdings stock is a Hold with a HK$13.50 price target.
Tip Ranks·